RxDoctor Payments Data

Amanda Smith

Nurse Practitioner · Appleton, WINPI 1306010004

Payments from drug & device makers

$1,971in general payments, 2019–2025

Across 63 payments — averaging $31.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$709
  • Abbott$648
  • Dexcom, Inc.$181
  • BETA Bionics, Inc.$123
  • Novo Nordisk$106
  • Amgen$36
  • plus $168 from 8 others

What the payments were for

  • Food & beverage$1,403100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,971 in reported general payments places this provider in the 95th percentile of 3,478 nurse practitioner providers in Wisconsin.

See all nurse practitioner providers in Wisconsin

Medicare billing

Part B allowed, 2024
$30,822
Medicare patients
104
Services billed
735

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide204$228,222
JardianceEmpagliflozin155$193,858
MounjaroTirzepatide93$113,729
TrulicityDulaglutide87$107,524
Humalog Kwikpen U-200Insulin Lispro29$86,244
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog40$71,890
FarxigaDapagliflozin Propanediol60$57,294
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog67$51,429
InvokanaCanagliflozin49$42,469
Humalog Kwikpen U-100Insulin Lispro92$37,763
Lantus SolostarInsulin Glargine,hum.Rec.Anlog235$30,496
Tresiba Flextouch U-200Insulin Degludec21$28,436
Tresiba Flextouch U-100Insulin Degludec43$28,365
Novolog FlexpenInsulin Aspart115$22,979
Fiasp FlextouchInsulin Aspart (Niacinamide)26$20,700

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Novolog$106$234,732222 claims
Lilly USA, LLCMounjaro, Trulicity, Humalog$27$225,757206 claims
AstraZenecaFarxiga$16$57,29460 claims
Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus$25$20,34736 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,478 nurse practitioner providers in Wisconsin.

Other nurse practitioner in Appleton

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →